XYXinyu Yang

Xinyu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinyu Yang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Guoping Li

    Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    2 shared publications
  • Hongcai Shang

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

    2 shared publications
  • Ji Lei

    Penn Transplant Institute, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    2 shared publications
  • Aidan C. Manning

    Medical Sciences Program, Indiana University, Bloomington, IN 47405, USA

    1 shared publication
  • Chengyu Li

    Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

    1 shared publication
  • Chengyu Li

    Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Urumqi 830046, China

    1 shared publication

Latest Publications

  • Wenxin Granules Prevent Ibrutinib‐Associated Atrial Fibrillation Through Restoring Redox Balance and Calcium Homeostasis

    by Xinyu Yang, Hao Yang, Na An, Fan Yang, Linke Jiao, Donghua Yang, Jie Zhao, Yonghong Gao, Yanwei Xing, Hongcai Shang

    Background: Ibrutinib, a frontline therapy for chronic lymphocytic leukemia (CLL), has been associated with an approximately 10‐fold increased risk of atrial fibrillation (AF) during treatment. Wenxin Granules, as a multi‐component and multi‐target drug, exert therapeutic effects on AF. Methods: We conducted electrophysiological studies in ibrutinib‐treated mice models to assess AF inducibility and the therapeutic efficacy of Wenxin Granules. Through network pharmacology screening, we identified potential molecular targets of Wenxin Granules. Subsequent proteomic analysis revealed specific targets through which Wenxin Granules may prevent ibrutinib‐associated AF. These targets were further validated in mice model experiments. Results: Our study demonstrates that Wenxin Granules treatment in mice significantly reduces AF inducibility, shortens AF duration, and attenuates pathological cardiac remodeling, including left atrial (LA) enlargement and myocardial fibrosis ( p < 0.05). Through comprehensive analysis integrating proteomics with network pharmacology‐predicted molecular targets, we systematically screened and identified 25 core therapeutic targets of Wenxin Granules, which are primarily associated with oxidative stress and calcium protein‐related signaling pathways. The ibrutinib treatment group demonstrated significantly elevated expression of reactive oxygen species (ROS)‐related proteins, including NOX2, NOX4, p22‐phox, and XO. Additionally, ibrutinib substantially increased the expression of ox‐CaMKII, p‐CaMKII (Thr‐286), and p‐RyR2 (Ser2814), resulting in enhanced abnormal sarcoplasmic reticulum (SR) Ca 2+ release, altered mitochondrial structures, and atrial fibrosis. Notably, Wenxin Granules administration reduced the expression of these proteins ( p < 0.05). Conclusions: These findings demonstrate that Wenxin Granules can ameliorate the occurrence and progression of AF induced by ibrutinib treatment, thereby laying the groundwork for further research and potential clinical applications in AF therapy.

  • Open Access

    miRNA-Targeted Herbal Compounds Against Gastric Precancerous Evolution in Chronic Atrophic Gastritis

    by Chenlin Wang, Nan Zhang, Xiaoge Wang, Xinyu Yang, Erping Xu

    Gastric cancer (GC) ranks third globally in cancer mortality. It develops via a well-defined pathological sequence: normal gastric mucosa progresses sequentially to superficial gastritis, chronic atrophic gastritis (CAG), intestinal metaplasia, dysplasia, and ultimately invasive carcinoma. Given this stepwise carcinogenic cascade, early intervention during the precancerous stage, particularly in CAG, is paramount for secondary GC prevention. Emerging evidence underscores that microRNAs (miRNAs), a major subclass of non-coding RNAs (ncRNAs), exert crucial regulatory effects on gastric carcinogenesis. Dysregulated miRNAs are frequently detected in Helicobacter pylori-infected gastric mucosa, driving chronic inflammation, epithelial-mesenchymal transition (EMT), and subsequent malignant transformation. Recently, traditional Chinese medicine (TCM) has gained increasing recognition as a promising therapeutic approach for precancerous lesions of gastric cancer (PLGC). Classical TCM formulations and bioactive herbal compounds have been shown to exert multi-targeted and multi-pathway efficacy in inhibiting the progression of this disease. This review integrates available evidence and indicates that TCM interventions, including herbal prescriptions and acupuncture, exert anti-inflammatory, anti-fibrotic and anti-metastatic effects by regulating microRNA expression profiles, thereby alleviating chronic inflammation, pathological remodeling and tumor cell invasion. Collectively, these findings demonstrate TCM’s adjunctive potential in CAG treatment and GC prevention, providing a novel mechanistic approach to halt precancerous gastric carcinogenesis.

  • Oligodendrocytes at the crossroads: Central players and interactive partners in white matter aging

    by Xinxin Zhang, Peiyao Yu, Yicheng Chen, Yanzhi Xu, Ruofei Xu, Xinyu Yang, Shichao Lv, Hongcai Shang, Yue Hu


  • Open Access

    Chinese Herbal Medicines for Diabetic Cardio‐Cerebrovascular Diseases: Key Bioactive Metabolites and Action Mechanisms

    by Ying Su, Shuwen Luo, Wei Li, Cuicui Cheng, Xinyu Yang, Zhen Xing

    Currently, the global incidence of diabetes is increasing, particularly in populous developing regions. In China, over 290 million people are affected by diabetic cardio‐cerebrovascular diseases. These diseases account for more than 40% of deaths and impose a significant economic burden on both society and families. Diabetes can result in vascular complications through multiple mechanisms, including cardiovascular and cerebrovascular diseases. Current management guidelines recommend conducting risk assessments before prescribing medications like antihypertensives, hypoglycemics, and lipid‐lowering drugs, alongside lifestyle interventions, to help prevent cardio‐cerebrovascular diseases. However, pharmacological approaches have several limitations, including adverse drug reactions and variability in patient responses. Chinese herbal medicine (CHM) exerts its therapeutic effects via bioactive metabolites that modulate multiple molecular targets, including enzymes, receptors, and transcriptional regulators, through complex interactions with cellular signaling networks. While modern pharmacological research validates its polypharmacological mechanisms, concerns persist regarding potential botanical drug interactions, toxicological profiles, and pharmacokinetic variability of certain botanicals. Only through a balanced scientific approach can CHM’s unique therapeutic value be fully realized. This review evaluates the efficacy of CHM in mitigating metabolic disorders, focusing on its diverse pharmacological mechanisms, including antioxidant defenses, inflammation suppression, and programmed cell death regulation. It elucidates the role of pivotal signaling cascades, including the glucagon (GLC)/5′‐adenosine monophosphate–activated protein kinase (AMPK)/nuclear transcription factor‐κB (NF‐κB) axis, the GLC/peroxisome proliferator–activated receptor α (PPARα)/PGC‐1α pathway, as well as the PI3K/Akt and AMPK/mammalian target of rapamycin (mTOR) signaling pathway, alongside oxidative stress and inflammatory responses. However, future research should prioritize well‐structured clinical trials and mechanistic studies to substantiate CHM’s therapeutic potential.


  • Top Cited Papers

    A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy

    by Guoping Li, Lingfei Sun, Cuiyan Xin, Tian Hao, Prakash Kharel, Aidan C. Manning, Christopher L. O'COnnor, Henry Moore, Shuwen Lei, Priyanka Gokulnath, et al.

    Transfer RNA-derived small RNAs (tsRNAs, or tDRs) perform a range of cellular functions. Here, we showed that a hypoxia-induced tDR, derived from the 3′ end of tRNA-Asp-GTC (tRNA-Asp-GTC-3′tDR), activated autophagic flux in kidney cells, while its silencing blocked autophagic flux. Functional gain/loss-of-function studies in murine kidney disease models demonstrated a significant reno-protective function of tRNA-Asp-GTC-3′tDR. Mechanistically, tRNA-Asp-GTC-3′tDR assembled stable G-quadruplex structures and sequestered pseudouridine synthase PUS7, preventing catalytic pseudouridylation of histone mRNAs. The resulting pseudouridylation deficiency directed histone mRNAs to the autophagosome-lysosome pathway, triggering RNA autophagy. This tDR-induced RNA autophagy pathway was activated during murine and human kidney diseases, suggesting clinical relevance. Thus, tRNA-Asp-GTC-3′tDR plays a role in regulating RNA autophagy, which helps to maintain homeostasis in kidney cells and protects against kidney injury.


  • Open Access

    Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity

    by Pan Feng, Fan Yang, Dongmei Zang, Dapeng Bai, Liyan Xu, Yueyun Fu, Ranran You, Tao Liu, Xinyu Yang

    Chemotherapy-induced cardiotoxicity is a major adverse effect, driven by multiple factors in its pathogenesis. Notably, RNAs have emerged as significant contributors in both cancer and heart failure (HF). RNAs carry genetic and metabolic information that mirrors the current state of cells, making them valuable as potential biomarkers and therapeutic tools for diagnosing, predicting, and treating a range of diseases, including cardiotoxicity. Over 97% of the genome is transcribed into non-coding RNAs (ncRNAs), including ribosomal RNA (rRNAs), transfer RNAs (tRNAs), and newly identified microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs). NcRNAs function not only within their originating cells but also in recipient cells by being transported through extracellular compartments, referred to as extracellular RNAs (exRNAs). Since ncRNAs were identified as key regulators of gene expression, numerous studies have highlighted their significance in both cancer and cardiovascular diseases. Nevertheless, the role of ncRNAs in cardiotoxicity remains not fully elucidated. The study aims to review the existing knowledge on ncRNAs in Cardio-Oncology and explore the potential of ncRNA-based biomarkers and therapies. These investigations could advance the clinical application of ncRNA research, improving early detection and mitigating of chemotherapy-induced cardiotoxicity.


  • Open Access

    Extracellular Non-Coding RNAs in Cardiovascular Diseases

    by Zeyidan Jiapaer, Chengyu Li, Xinyu Yang, Lingfei Sun, Emeli Chatterjee, Lingying Zhang, Ji Lei, Guoping Li

    Cardiovascular diseases (CVDs) remain the world’s leading cause of death despite the best available healthcare and therapy. Emerging as a key mediator of intercellular and inter-organ communication in CVD pathogenesis, extracellular vesicles (EVs) are a heterogeneous group of membrane-enclosed nano-sized vesicles released by virtually all cells, of which their RNA cargo, especially non-coding RNAs (ncRNA), has been increasingly recognized as a promising diagnostic and therapeutic target. Recent evidence shows that ncRNAs, such as small ncRNAs, circular RNAs, and long ncRNAs, can be selectively sorted into EVs or other non-vesicular carriers and modulate various biological processes in recipient cells. In this review, we summarize recent advances in the literature regarding the origin, extracellular carrier, and functional mechanisms of extracellular ncRNAs with a focus on small ncRNAs, circular RNAs, and long ncRNAs. The pathophysiological roles of extracellular ncRNAs in various CVDs, including atherosclerosis, ischemic heart diseases, hypertension, cardiac hypertrophy, and heart failure, are extensively discussed. We also provide an update on recent developments and challenges in using extracellular ncRNAs as biomarkers or therapeutical targets in these CVDs.


  • Open Access

    Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial

    by on behalf of the DIRECTION investigators, Xiaoyu Zhang, Guihua Tian, Zhaofeng Shi, Yang Sun, Jiayuan Hu, Yin Jiang, Rui Zheng, Shiqi Chen, Chengyu Li, et al.

    Background: No treatment has convincingly been proven to be beneficial for microvascular obstruction (MVO) in patients with ST-elevation myocardial infarction (STEMI). Several studies have described the effects of Danhong Injection. However, evidence of a rigorously designed verification study is still lacking, and the intervention timing of Danhong Injection is uncertain. Methods: The DIRECTION study is a multicenter, prospective, randomized, evaluator-blind study. A total of 336 patients with STEMI receiving percutaneous coronary intervention (PCI) will be randomly assigned to conventional treatment, the preoperative Danhong Injection, or the postoperative Danhong Injection. The primary outcome is rate of ST-segment resolution (STR) ≥ 70% at 90 min after PCI. The secondary outcomes are the degree of STR, Thrombolysis in Myocardial Infarction (TIMI) flow grade, TIMI myocardial perfusion grade, left ventricular ejection fraction, N-terminal prohormone brain natriuretic peptide, high-sensitivity C-reactive protein, and infarct size expressed as area under the curve for cardiac troponin I (cTnI) and for creatine kinase MB. The major adverse cardiovascular events and hospital readmission events will be recorded. Health quality will be assessed with the 12-item Short Form Health Survey. The safety outcomes include bleeding events, adverse events, and abnormal changes in routine blood tests. Psychological status and dietary patterns will be evaluated using Hamilton Depression Rating Scale and Food Frequency Questionnaire as the relevant indicators. Discussion: This trial will evaluate the efficacy and safety of Danhong Injection, as well as its optimal timing of intervention to prevent MVO in patients with STEMI. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900021440. Registered on February 21, 2019.